Connect Biopharma Holdings Limited (CNTB) Fair Value 2026

CNTB · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.5 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (25/100)

Quick Summary — As of 2026-08-28, Connect Biopharma Holdings Limited (CNTB) trades at $2.23. QOC: 5.5/10. Value Trap Risk: 25/100 (LOW). 1/13 models active.

Key Facts

Ticker
CNTB
Price
$2.23
Quality Score
5.5/10
Value Trap Risk
25/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give CNTB?

1 Intrinsic Value Models vs. Current Price ($2.23)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.89 -60.2%

All Models Active

All 1 models are displayed above.

What Is Connect Biopharma Holdings Limited (CNTB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Connect Biopharma Holdings Limited's intrinsic value is estimated at $0.89, suggesting the stock is overvalued at its current price of $2.23. With 1 out of 1 models flagging downside (-60.2% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About CNTB?

1 of 13 models are currently active for CNTB. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does CNTB Rank in Biotechnology?

Among 625 Biotechnology stocks, CNTB ranks #220 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Connect Biopharma Holdings Limited competes in an environment where cash runway (months) often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is CNTB a Value Trap?

CirclFi's Value Trap algorithm assigns CNTB a score of 25/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Connect Biopharma Holdings Limited. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Connect Biopharma Holdings Limited is rated at 5.5/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CNTB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CNTB's 1 active models, average confidence is 54%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Connect Biopharma Holdings Limited Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

IPHAInnate Pharma S.A.QOC 5.5CAPRCapricor Therapeutics, Inc.QOC 5.4SRRKScholar Rock Holding CorporationQOC 5.5IRDOpus Genetics, Inc.QOC 5.4GNLXGenelux CorporationQOC 5.5IBIOiBio, Inc.QOC 5.4QNCXQuince Therapeutics, Inc.QOC 4.8OSTXOS Therapies IncorporatedQOC 4.0CSBRChampions Oncology, Inc.QOC 6.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: IPHA · CAPR · SRRK · IRD · GNLX · IBIO · QNCX · OSTX · CSBR · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CNTB?

7 companies across all industries closest to CNTB’s Quality of Company score of 5.5/10.

GFMHGoliath Film and Media HoldingsQOC 5.5HSDTSolana CompanyQOC 5.5AMCIAMC Robotics CorporationQOC 5.5BTCSBTCS Inc.QOC 5.5MWHSOLV Energy, Inc.QOC 5.5EDRYEuroDry Ltd.QOC 5.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GFMH · HSDT · AMCI · BTCS · MWH · EDRY · NVDA

Where Does CNTB Sit in CirclFi's Biotechnology Rankings?

CNTB is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Connect Biopharma Holdings Limited’s Valuation?

What is Connect Biopharma Holdings Limited's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Connect Biopharma Holdings Limited (CNTB). The Quality of Company score is 5.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CNTB overvalued or undervalued right now?

At $2.23, 0 of 1 active models suggest CNTB may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Connect Biopharma Holdings Limited's business model in Biotechnology.

What does a Quality of Company score of 5.5 mean for CNTB?

Connect Biopharma Holdings Limited's QOC of 5.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CNTB?

CirclFi analyzes CNTB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is CNTB a value trap in 2026?

Connect Biopharma Holdings Limited's Value Trap score is 25/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Connect Biopharma Holdings Limited (CNTB) a Quality of Company score of 5.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CNTB/ · Methodology
Primary sources for this CNTB valuation
  • Financial statements: Connect Biopharma Holdings Limited 10-K and 10-Q filings on SEC EDGAR (CIK 0001835268) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CNTB as of ; valuations recomputed .